Epeleuton is under clinical development by Afimmune Biopharma and currently in Phase II for Sickle Cell Disease. According to GlobalData, Phase II drugs for Sickle Cell Disease have a 59% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Epeleuton’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Epeleuton overview
Epeleuton (AF-102) is under development for the treatment of rare blood disorders and sickle cell disease. It is a bioactive lipid administered orally as a capsule.
It was under development for idiopathic pulmonary fibrosis, type-2 diabetes, hypertriglyceridemia, non alcoholic fatty liver disease (NAFLD), idiopathic pulmonary fibrosis, alcoholic hepatitis, non-alcoholic steatohepatitis (NASH), cardiovascular risk reduction, chronic obstructive pulmonary disease (COPD), Coronavirus disease 2019 (COVID-19) and atherosclerosis.
Afimmune Biopharma overview
AFIMMUNE Biopharma is a developer of drugs designed to work on inflammatory conditions of the primary organs including the heart and the liver. The company is headquartered in Dublin City, Dublin, Ireland.
For a complete picture of Epeleuton’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
